By Staff
Friday, July 26, 2024 12:27 AM
PARIS, France—
EssilorLuxottica announced revenue growth of 5.2 percent for the second quarter of 2024 at constant exchange rate and 5.3 percent for the first half of the year. The company also reported expanding margins and the acquisitions of diagnostic med-tech platform
Heidelberg Engineering and iconic
Supreme brand, as reported in
VMAIL, which were announced on July 17, 2024.
By Staff
Thursday, July 25, 2024 12:27 AM
PARIS—
Kering Eyewear, part of the global luxury group Kering, has reported revenue of €914 million in the first half of 2024, up 5 percent as reported and up 6 percent on a comparable basis. In the second quarter, Kering Eyewear's sales rose by 3 percent both on a comparable basis and as reported, driven by solid progression of the brands in its portfolio, the Group said. Overall, revenue from the Kering Eyewear and Corporate segment amounted to €1.1 billion for the first half of 2024, mainly attributable to activities of Kering Eyewear and Kering Beauté, the latter including the sales of Creed.
By Staff
Friday, July 19, 2024 12:24 AM
CHARENTON-LE-PONT, France and MENLO PARK, Calif.—Facebook and Instagram owner
Meta (NASDAQ: META) is reported to be in talks with
EssilorLuxottica (Reuters: ESLX.PA) to purchase a small stake in the eyewear company, according to reports yesterday from the
Financial Times,
The Wall Street Journal and other leading financial publications that cited sources close to the companies. EssilorLuxottica declined to comment when contacted by
VMAIL. Meta also declined, with a spokesperson saying “they had no comment on the speculation.” According to the
WSJ report, “the talks are continuing and may not result in a deal.”
By Staff
Thursday, July 18, 2024 12:24 AM
NEW BRUNSWICK, N.J.—
Johnson & Johnson (NYSE: JNJ) has reported 2024 second quarter sales growth of 4.3 percent to $22.4 billion, with operational growth of 6.6 percent. Reported second quarter sales in the U.S. totaled $12.6 billion, a 7.8 percent increase over the same period last year, the company announced. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth,” said Joaquin Duato, chairman and chief executive officer.
By Staff
Wednesday, July 17, 2024 12:21 AM
HAMBURG, Germany—The
Fielmann Group, a global eyewear provider, reported 12 percent sales growth year-over-year for the first half of 2024 as well as improved profitability. According to preliminary figures, the company generated consolidated sales of around €1.1 billion in the first half of 2024.
By Staff
Monday, July 15, 2024 12:18 AM
RAHWAY, N.J.—
Merck, a research-intensive biopharmaceutical company known as MSD outside of the U.S. and Canada, has announced the completion of the acquisition of
Eyebiotech Limited, a privately held ophthalmology-focused biotechnology company.
By Staff
Friday, July 12, 2024 12:24 AM
EMERYVILLE, Calif.—
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare, skin care and wound care products, has announced preliminary net revenue of $2.4 million for the second quarter of 2024 and $5.0 million for the first half of 2024, primarily derived from the company’s eyecare products. Net revenue from the company’s eyecare products increased by 9 percent for both the second quarter and the first half of 2024 compared with the corresponding periods in 2023, the company noted. NovaBay also said it expects 2024 net revenue from the company’s eyecare products to be approximately $10 million.
By Staff
Friday, July 5, 2024 12:24 AM
VANCOUVER, British Columbia—
KITS Eyecare Ltd. (TSX: KITS), a vertically integrated eyecare provider, has provided selected preliminary unaudited results for the second quarter ended June 30, 2024. According to the company, total revenue grew 25 percent year-over-year to approximately $37.5 million. The company also reported that adjusted EBITDA increased year-over-year to over 3 percent of revenue and that it finished the second quarter with a cash balance of more than $19.0 million.
By Staff
Friday, July 5, 2024 12:21 AM
LONDON and CAMBRIDGE, Mass.—
Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company that works to save and restore the vision of patients with blinding retinal diseases, has announced it has raised $170 million in Series B funding to advance the development of ophthalmic gene therapies.
By Staff
Monday, June 17, 2024 12:21 AM
ALISO VIEJO, Calif.—
Glaukos Corporation, an ophthalmic pharmaceutical and medical tech company, has announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 2.75 percent convertible senior notes due 2027.
By Staff
Friday, May 31, 2024 12:30 AM
CooperCompanies announces Q2 2024 financial results; KeraLink International names a new president and CEO; Merck to acquire EyeBio; CooperCompanies publishes 2023 ESG report; and The Vision Council releases new inSights research all topped this week’s
VMAIL news feed. Click on the headlines below to catch up on anything you might have missed.
By Staff
Friday, May 31, 2024 12:27 AM
SAN RAMON, Calif.—
CooperCompanies (Nasdaq: COO), a global medical device company, has announced financial results for its fiscal second quarter ended April 30, 2024. CooperCompanies reported revenues under two major segments—CooperVision (CVI) and CooperSurgical (CSI). The company reported that overall revenue increased 7 percent year-over-year to $942.6 million. CVI revenue was up 8 percent to $635.9 million and CSI revenue grew 6 percent to $306.7 million, according to the announcement. "I'm pleased to report record quarterly revenues and great operational progress throughout the organization," said Al White, Cooper's president and CEO.
By Staff
Thursday, May 30, 2024 12:21 AM
RAHWAY, N.J. and NEW YORK—
Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and
Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which
Merck, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone payments, the announcement stated. The acquisition has been unanimously approved by the EyeBio board of directors.
By Staff
Thursday, May 30, 2024 12:18 AM
MIAMI—
Innovative Eyewear, Inc., a developer and seller of smart eyewear, has announced that it has entered into a definitive agreement for the issuance and sale of 5,263,161 shares of its common stock at a purchase price per share of $0.475 in a registered direct offering priced at-the-market under Nasdaq rules.
By Staff
Friday, May 24, 2024 12:24 AM
MARLBOROUGH, Mass.—
BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has announced its financial results for the thirteen weeks ended May 4, 2024. Total comparable club sales increased by 1.6 percent in the first quarter of fiscal 2024 compared with the first quarter of fiscal 2023.